Karyopharm Therapeutics Inc.
USPTO PatentsView assignee record - 37 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Karyopharm ranks #8,620 of 49,997 tracked US assignees by granted-patent volume, with 37 patents across 6 technology areas.
- #8,620
- of 49,997 US assignees by volume
- 43rd percentile
- by Innovation Score (33.1/100)
- 15.5
- avg claims per patent
- -43%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R8620 · US Corporation #8,620 · 37 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-SMALL 37 grants
- UPPER-Q #8,620/49,997
- PHOTO-FINISH Kadtc Pet Supplies
- CPC-NARROW A61P · 6 areas
- INNOV-THIN 33.1/100
- CLAIMS-RICH 15.5 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -43% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Kadtc Pet Supplies Inc (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Karyopharm’s 33.1 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Karyopharm
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Cognito Therapeutics · near 33
Cognito Therapeutics · near
33 score
- Karyopharm Therapeut… · this assignee 33
Karyopharm Therapeut… · this assignee
33 score
- Synaptics Display… · near 33
Synaptics Display… · near
33 score
- Tecmen · near 33
Tecmen · near
33 score
- Umbra · near 33
Umbra · near
33 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Karyopharm's Innovation Score is 33.1/100 (43rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Karyopharm?
Each dot is one of Karyopharm’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Karyopharm’s own 15.5 claims/patent is at or below the 17.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Karyopharm's grants concentrate
Karyopharm Therapeutics Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (6 grants) versus a trough of 1 in 2024. By volume, Karyopharm sits between KIP Prod P1 LP and Lensvector.
Karyopharm's three-year grant acceleration
Karyopharm Therapeutics Inc. shows 5 grants in 2022–2024 against only 13 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Karyopharm's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- KIP Prod P1
KIP Prod P1 LP
37 patents
- Klox
Klox Technologies Inc.
37 patents
- Krosakiharima
Krosakiharima Corporation
37 patents
- Kadtc Pet Supplies
Kadtc Pet Supplies Inc
37 patents
- Ketra
Ketra, Inc.
37 patents
- Khalifa Universit…
Khalifa University of Science, Technology and Research
37 patents
- Kite Pharma
Kite Pharma, Inc.
37 patents
- Lensvector
Lensvector
37 patents
- Karyopharm Therap… ◀
Karyopharm Therapeutics Inc.
37 patents
What this shows Karyopharm holds 37 patents at rank #8,623, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Karyopharm
By rank, the assignees closest to #8,623 in granted patent volume.
- KIP Prod P1 LP #8,619 · 37 patents
- Klox Technologies Inc. #8,620 · 37 patents
- Krosakiharima Corporation #8,621 · 37 patents
- Kadtc Pet Supplies Inc #8,622 · 37 patents
- Ketra, Inc. #8,624 · 37 patents
- Khalifa University of Science, Technology and Research #8,625 · 37 patents
- Kite Pharma, Inc. #8,626 · 37 patents
- Lensvector #8,627 · 37 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Karyopharm's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Karyopharm, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Karyopharm ranks #502 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (33 here).
Karyopharm's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
33 43rd percentile higher than 43% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 4 | 10.8% |
| 2016 | 3 | 8.1% |
| 2017 | 4 | 10.8% |
| 2018 | 4 | 10.8% |
| 2019 | 6 | 16.2% |
| 2020 | 3 | 8.1% |
| 2021 | 4 | 10.8% |
| 2023 | 4 | 10.8% |
| 2024 | 1 | 2.7% |
| 2025partial year | 4 | 10.8% |
Which technologies does Karyopharm Therapeutics Inc. patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Karyopharm Therapeutics Inc.'s patent record in context - here's where to go next.
- Karyopharm Therapeutics Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #8,620 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Karyopharm Therapeutics Inc. against KIP Prod P1 LP, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 33.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.